News

ELIQUENT Expands Pharmacovigilance Expertise with Shelley Gandhi

ELIQUENT Expands Pharmacovigilance Expertise with Shelley Gandhi

ELIQUENT Welcomes Shelley Gandhi to Enhance Pharmacovigilance

ELIQUENT Life Sciences, a known regulatory consulting firm dedicated to innovation in healthcare, is thrilled to announce the addition of Shelley Gandhi, a highly respected expert in pharmacovigilance (PV). This move strengthens ELIQUENT's commitment to providing integrated compliance solutions and enhances their capability to manage risks while accelerating product market entry.

Bringing Global Expertise to ELIQUENT

With over thirty years of experience in PV and risk management, Shelley Gandhi is set to make a significant impact at ELIQUENT. Her extensive tenure with the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has equipped her with a deep understanding of European regulatory processes related to ensuring the safety of medicinal products. Gandhi's time at the MHRA, where she held several senior roles, allowed her to gain vital insights into regulatory expectations which are essential for effective risk management.

Impactful Contributions at the European Medicines Agency

During her illustrious career, Shelley served as the UK representative on the EudraVigilance Expert Working Group, directly shaping the European Medicines Agency’s system for managing reports of suspected adverse medicine reactions. Her role was crucial in refining key pharmacovigilance processes throughout Europe, proving her expertise invaluable.

Expanding Pharmacovigilance Solutions

Before joining ELIQUENT, Gandhi dedicated more than a decade to providing strategic PV advice and support to biotechnology firms. Her vast knowledge spans various therapeutic areas, from initial clinical development phases to launch preparations, making her exceptionally qualified to address the unique needs of clients.

A Proactive Approach to Drug Safety and Compliance

At ELIQUENT, Shelley collaborates with clients to ensure adherence to global safety regulations and anticipates necessary adjustments to compliance protocols. Her extensive background in risk management amplifies the firm's capabilities to provide comprehensive PV and Risk Management Solutions in an evolving global landscape.

Comprehensive Pharmacovigilance & Risk Management Services

ELIQUENT’s expanded PV solutions are designed to provide efficient practices that guarantee compliance across different markets. The firm combines decades of experience from its leadership in both public and private sectors to support clients in navigating challenges associated with post-marketing surveillance and adverse event reporting.

Within this evolving regulatory environment, ELIQUENT’s tailored Pharmacovigilance and Risk Management Solutions include:

  • Global Support: Expert guidance in navigating global PV regulations.
  • Adverse Event Reporting: Comprehensive strategies for identifying and responding to adverse events.
  • Regulatory Reporting: Proficient handling of complex regulatory reporting demands.
  • Signal Detection: Advanced processes for reporting and communicating risk effectively.
  • Risk Assessment & Management: Early identification and planning to manage potential risks.
  • Post-Marketing Surveillance: A network of experts to ensure product safety and reporting functions.
  • Risk Communications: Development of communication plans to handle safety concerns.
  • Clinical Trials Safety Oversight: Resources dedicated to monitoring safety pre- and post-approval.
  • Qualified Person for Pharmacovigilance (QPPV): Ensuring client compliance with pharmacovigilance regulations.
  • Global PV Training: Customized training programs to maintain outstanding regulatory standards.

Integrated Service Platform at ELIQUENT

ELIQUENT offers a redefined regulatory consulting experience, ensuring comprehensive support across the product lifecycle. The firm’s platform comprises a collaboration of regulatory leaders, industry experts, and technical specialists, streamlining the process of bringing new therapies to market.

Key integrated service offerings at ELIQUENT include:

  • Regulatory Affairs Solutions: Navigating clients from innovation through approvals and beyond.
  • Pharmacovigilance & Risk Management Solutions: Empowering operations with confidence.
  • Quality & Compliance Solutions: Tailored compliance strategies tailored to client needs.
  • Remediation Solutions: Expert guidance to navigate remediation challenges.
  • Talent Solutions: Scalable teams equipped with the right expertise.

About ELIQUENT Life Sciences

ELIQUENT Life Sciences is a collective of six esteemed regulatory consulting firms, including Validant and Greenleaf Health, uniting to provide unparalleled solutions for pharmaceutical and biotech companies. Their extensive service portfolio enables innovators to navigate complex regulatory paths across various therapeutic areas. With continued backing from leading investors, ELIQUENT remains dedicated to facilitating compliance and authorization for a diverse range of healthcare products.

Frequently Asked Questions

What is ELIQUENT Life Sciences known for?

ELIQUENT Life Sciences specializes in regulatory consulting, offering extensive support in pharmacovigilance and risk management for the healthcare industry.

Who is Shelley Gandhi?

Shelley Gandhi is a renowned expert in pharmacovigilance with over 30 years of experience, recently joining ELIQUENT to enhance its service offerings.

What are the main services provided by ELIQUENT?

ELIQUENT provides services including regulatory affairs, pharmacovigilance, risk management, quality and compliance, and talent solutions.

How does ELIQUENT support clients in compliance?

ELIQUENT offers global support and strategic advice to ensure clients adhere to safety standards and regulatory requirements effectively.

Why is pharmacovigilance important in healthcare?

Pharmacovigilance is crucial for monitoring the safety of medicinal products, preventing adverse reactions, and ensuring patient safety during and after drug approval.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Biointron's RushDATA™: Speeding Up Antibody Discovery

Updated Category News Views 207

A New Chapter in Antibody Discovery Well, color me intrigued. Biointron, a name you'd recognize if you've got even a toe in the biotech pond, just threw a serious curveball into the antibody discovery game with RushDATA™—an AI- and machine learning-driven platform that's packing a punch. And it's not just about throwing tech buzzwords around; this thing clocks...

Continue Reading
First Horizon's $25M Bet: New Center Transforms Houston

Updated Category News Views 157

New Markets Tax Credits: A Game Changer First things first, if you're thinking this is some typical charitable write-off, think again. First Horizon Bank (NYSE: FHN) is deep in the mix of something pretty transformative in the world of finance and community support. They're not just throwing money at a problem and hoping it sticks. Nope, we're talking real strategy with a...

Continue Reading
When to Switch Your LLC to S Corp Status: Tips

Updated Category News Views 79

Is Your LLC Ready for the S Corp Leap? Thinking about shifting your LLC to S corporation status? You're not alone—many business owners hit this fork in the road as their enterprise starts rolling in more dough. And if you're scratching your head wondering if this switch makes sense for your venture, listen up because timing and context are everything here. When Should...

Continue Reading
Will Hair Loss Drugs Challenge Transplant Clinics?

Updated Category News Views 73

Emerging Treatments Stir Up Hair Loss Scene You ever get the feeling we're on the brink of something big? That's where we are with hair loss treatments, folks. As of late 2026, new drugs are making waves in clinical trials, but they’re not yet giving hair transplant clinics any sleepless nights. Smile Hair Clinic's co-founders, Dr. Mehmet Erdo?an and Dr. Gökay Bilgin,...

Continue Reading
SPOC Energy's Hiring Push Signals Growth Surge

Updated Category News Views 64

A Growing Workforce for a Growing Demand Here we are, smack dab in a bustling week of business news, and among it, SPOC Energy is ramping up its workforce across Alabama. Now, SPOC isn't any run-of-the-mill operation; this Birmingham-based manufacturer messes around with advanced power conversion systems and motor-control automation—a mouthful, sure, but critical stuff...

Continue Reading
Foreigner to Rock Irvine with Night Ranger in 2027

Updated Category News Views 85

Irvine Set for a Rock Revival Talk about a blast from the past! On March 27, 2027, two titans of the rock world, Foreigner and Night Ranger, are set to ignite Irvine like it's the glory days of arena rock all over again. Hosted at the Great Park Live, this show isn't just a concert—it's a full-scale invasion of rock's golden age right into Southern California's heart....

Continue Reading
Philip Scroggie's Legacy in Global Energy Projects

Updated Category News Views 116

A Lifetime of Energy Industry Excellence When you've been around the block in the energy sector as long as Philip D. Scroggie has, you're bound to pick up a few accolades. Recognized as an Inner Circle Lifetime Member, this guy has etched his name in the annals of global energy project management. Yeah, he's been a heavyweight in the oil, gas, and LNG industries, and he's...

Continue Reading
TruGreen Finds New Growth in Birch Hill Acquisition

Updated Category News Views 204

TruGreen's New Chapter Begins In the world of lawn care, TruGreen is sowing the seeds for a revitalized future, courtesy of its recent acquisition by Birch Hill Equity Partners. Based out of Franklin, Tennessee, this powerhouse in the green arena is set to start a fresh chapter, swapping partners like old gloves after a long, 19-year stint with Clayton, Dubilier & Rice...

Continue Reading
The Melt Expands with Key Texas Franchise Deal

Updated Category News Views 130

Throwing Down the Gauntlet: The Melt Expands If there's one thing I've learned after decades watching these restaurant chains multiply like rabbits it’s this: when a veteran gets involved, you perk up. The Melt has done just that by roping in Syed Ahmad—a name that actually means something in this game—to open eight new locations in the Lone Star State. It isn't...

Continue Reading
ADI Global Faces Investor Investigation Over Major Write-Down

Updated Category News Views 60

Towering Goodwill Falls and Investor Scrutiny Well, let's dig into this mess ADI Global Distribution has found itself in. If you were hanging onto ADIG shares, your portfolio probably took quite the hit when they revealed a nasty $659 million goodwill write-down. Imagine opening up those financials and seeing about 62% of goodwill value wiped out overnight. Suddenly, that...

Continue Reading

Top 5 Most Recently Viewed Articles

Arvinas Reflects on Successful Year, Projecting Future Growth

Updated Category News Views 220

Arvinas' Notable Advances in 2024 Arvinas, Inc. (Nasdaq: ARVN), a pioneering clinical-stage biotechnology company, continues on its ambitious path, showing significant progress in 2024. The company has been steadfast in its mission to develop innovative therapies targeting debilitating diseases through its unique PROTAC platform. Their latest advancements signal a...

Continue Reading
Understanding NB Private Equity Partners and Their Recent Buyback

Updated Category News Views 256

NB Private Equity Partners Publishes Share Buyback Details Today, NB Private Equity Partners, commonly referred to as NBPE, has made significant strides to enhance its shareholders' value through a recent buyback of its Class A shares. This transaction, carried out in accordance with the general authority bestowed upon the company’s management by shareholders, showcases...

Continue Reading
China’s AI Innovations Enhance Global Development Efforts

Updated Category News Views 385

China’s Commitment to AI Development In recent years, China has made significant strides in artificial intelligence (AI) development, showcasing its dedication to fostering technological innovation and bolstering cooperation with nations around the world. One of the central aspects of this commitment was highlighted during a recent inspection tour by Chinese President...

Continue Reading
Exploring Crypto-Bound Stocks: A Guide to Peak Investments

Updated Category News Views 209

Bitcoin and Ethereum Driving Market Momentum Recently, Bitcoin experienced a significant breakout, surpassing its previous all-time high of around $112,000 and hitting new heights above $123,000. Although it has cooled off somewhat, it remains consolidated just above its previous resistance level, which now functions as a key support zone. With Bitcoin's year-to-date...

Continue Reading
Verra Mobility's Plunge: A 45% Stock Drop Shakes Investors

Updated Category News Views 147

Surprise Hit: Verra Mobility Takes a Blow Verra Mobility's situation feels like having a rug yanked out from under one's feet. The company sent its shareholders into a tailspin after disclosing a major hit: losing a contract with Avis, which accounted for more than 10% of its annual revenue. We're talking about a stock that nosedived roughly 45%—it's the kind of...

Continue Reading